Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 916-925

  Traini, Sara ^a   Piccolo, Enza ^a   Tinari, Nicola ^a   Rossi, Cosmo ^a   La Sorda, Rossana ^a   Spinella, Francesca ^b   Bagnato, Anna ^b   Lattanzio, Rossano ^a   D'Egidio, Maurizia ^a   Di Risio, Annalisa ^a   Tomao, Federica ^c   Grassadonia, Antonino ^a   Piantelli, Mauro ^a   Natoli, Clara ^a   Iacobelli, Stefano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BINDING PROTEIN; FOCAL ADHESION KINASE; LECTIN GALACTOSIDE BINDING SOLUBLE 3 BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SP 2; PROTEIN KINASE B; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; GLYCOPROTEIN; LGALS3BP PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUBULOGENESIS; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GLYCOPROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84912079538     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1117     Document Type: Article

References (25)

1. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 1998;17:1606-13.
2. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-7.
3. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-6.
4. Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, et al. High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer 2009;124:333-8.
5. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000;96:3282-5.
6. Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A, et al. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002;197:218-23.
7. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002;62:2535-9.
8. Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, et al. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med 2013;91:83-94.
9. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-10.
10. Tinari N, D'Egidio M, Iacobelli S, Bowen M, Starling G, Seachord C, et al. Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Biochem Biophys Res Commun 1997;232:367-72.
11. Silvestri B, Calderazzo F, Coppola V, Rosato A, Iacobelli S, Natoli C, et al. Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. Clin Exp Immunol 1998;113:394-400.
12. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006;16:210-20.
13. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 2009;69:2669-76.
14. Weidner N, Weinberg DS, Hardy SC, Hollister KA, Lidgard GP. Localization of nuclear matrix proteins (NMPs) in multiple tissue types with NM-200.4 (an antibody strongly reactive with NMPs found in breast carcinoma). Am J Pathol 1991;138:1293-8.
15. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 2010;207:1981-93.
16. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-56.
17. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995;1:120-2.
18. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004;19:551-6.
19. Bair EL, Nagle RB, Ulmer TA, Laferte S, Bowden GT. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 2006;66:283-93.
20. Iacovazzi PA, Guerra V, Elba S, Sportelli F, Manghisi OG, Correale M. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int J Biol Markers 2003;18:222-6.
21. Cesinaro AM, Natoli C, Grassadonia A, Tinari N, Iacobelli S, Trentini GP. Expression of the 90Ktumor-associated protein in benign andmalignant melanocytic lesions. J Invest Dermatol 2002;119:187-90.
22. Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S. Tyrosine kinase inhibitors. Curr Cancer Drug Targets 2010;10:462-83.
23. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
24. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treatedwithananthracyclineand a taxane. J Clin Oncol 2008;26:1810-6.
25. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21.